The newsletter provides important information pertaining to key reimbursement related events for new and existing office-administered products. Our newsletter is sent from on behalf of pharma manufacturers. The newsletter includes the following information: C-Code alerts, J-code alerts, NCCN alerts, New NDC alerts, Updates on Pricing information, and more. Click here to opt in to our newsletter.

Announcing Permanent J-Code for ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) – 1/24/24

Temporary C-Code for a New 4F-PCC Available January 1, 2024 – 1/22/24

Samsung Bioepis Biosimilar Market Report 4th Edition, Q1 2024 – 1/17/24

J9259 Paclitaxel protein-bound particles (American Regent) – 1/10/24

CMS Granted J-Codes for Chiesi Products – 1/9/24

Announcing a new Wholesale Acquisition Cost (WAC) for NEXPLANON® (etonogestrel implant) 68 mg Radiopaque – 1/2/24

Sponsored Message: New FDA Approval in Locally Advanced/Metastatic Urothelial Cancer (mUC) – 1/3/24

KEYTRUDA(R) (pembrolizumab): New Indication – 12/21/23